This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Wyeth Upbeat About Earnings

Wyeth (WYE) said Wednesday that several regulatory, research and manufacturing issues won't affect the company's estimated earnings for the year.

In fact, "if current business trends continue," Wyeth could produce full-year earnings per share at the upper end of the previously predicted range of $2.97 to $3.07, the company said after the markets had closed.

The prediction excludes any potential restructuring charges that could result from the company's continuing review of its business processes, Wyeth said. The consensus EPS forecast is $3.08, according to Thomson First Call.

"We expect to deliver on our stated goal of growing earnings at a meaningfully faster rate than revenue," said Robert Essner, chairman and CEO, in a prepared statement.

In regular trading, the stock lost 58 cents, or 1.3%, to close at $43.82. After hours, it lost another 2 cents.

Although the Madison, N.J., drugmaker is scheduled to release second-quarter results on July 20, it decided to inform investors about several recent developments that could affect its future sales and profit. They include a warning from the Food and Drug Administration about its manufacturing practices, additional clinical trials for an experimental antidepressant and a delay in launching a new oral contraceptive.

Wyeth sent a "timely response" to a May 8 warning letter from the FDA that cited problems at a Puerto Rico plant, based on an inspection that was conducted from early November through mid-December. "We are very disappointed to receive this letter from the FDA," said Essner in a telephone conference call with analysts.

The company said it has put a "comprehensive corrective action plan in place and is working with the regional FDA office to determine next steps," adding that it wants to address the agency's concerns as soon as possible.

Over the years, failure to act quickly or effectively on manufacturing problems by some drugmakers has led to the government's seizing products, imposing drastic fines or establishing lengthy monitoring programs. "Failure to make prompt corrections could result in regulatory action without further notice," said the FDA warning letter to Wyeth.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs